Clinical Significance and Diagnosis of Sarcopenia in Patients With Heart Failure With Preserved Ejection Fraction
试验速览
- 阶段
- 不适用
- 入组人数
- 190
- 试验地点
- 1
- 主要终点
- Arterial stiffness
研究概览
简要总结
Obesity sarcopenia, characterized by the coexistence of excess fat and muscle mass reduction, may contribute to the pathophysiology of exercise intolerance in patients with heart failure with preserved ejection fraction (HFpEF). The project will examine the impact of selected circulating miRNAs on processes that may form the pathophysiological basis for HFpEF development and obesity sarcopenia in correlation with biochemical markers, echocardiographic assessment and non-invasive assessment of hemodynamic parameters. In addition, the impact of LDL and HDL on these diseases will be assessed. Determinations of selected adipokines and asymmetric dimethylarginine will also be carried out and their effects on the cardiovascular system will be assessed.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 35 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •control group: healthy volunteers
- •study groups: patients with HFpEF. Patients in which the results of BNP/NT-proBNP did not confirm the diagnosis of HFpEF were classified as hypertensive group.
排除标准
- •coronary artery disease
- •unstable hypertension
- •heart failure class IV NYHA
- •condition after percutaneous or surgical revascularization
- •pulmonary hypertension in echocardiography
- •obstructive or restrictive lung diseases
- •congenital heart disease
- •arrhythmias (including atrial fibrillation)
- •pacemaker or implantable cardioverter defibrillator
- •hyperthyroidism or hypothyroidism
- •pregnancy or lactation
- •hemodynamically significant acquired heart defects
- •cardiomyopathies
- •GFR <60 ml/min/1.73 m2
- •other medical conditions such as: cancer, significant anemia, diabetes, alcohol and drug abuse, chronic inflammatory diseases and other
- •the patient's inability to cooperate and / or give informed consent to participate in the study
结局指标
主要结局
Arterial stiffness
时间窗: through study completion, an average of 1 year
Left ventricular systolic and diastolic function
时间窗: through study completion, an average of 1 year
The level of biochemical parameters
时间窗: through study completion, an average of 1 year
次要结局
未报告次要终点
研究者
Agata Bielecka-Dabrowa, MD, PhD, Department of Hypertension
Principal Investigator
Medical University of Lodz